Etoposide

For research use only. Not for use in humans.

Catalog No.S1225 Synonyms: VP-16, VP-16213

121 publications

Etoposide Chemical Structure

Molecular Weight(MW): 588.56

Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 91 In stock
USD 70 In stock
USD 280 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Etoposide has been cited by 121 publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Etoposide is a semisynthetic derivative of podophyllotoxin, which inhibits DNA synthesis via topoisomerase II inhibition activity.
Targets
Topo II [2]
(Cell-free assay)
In vitro

Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA, which induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [1] Etoposide inhibits the growth of murine angiosarcoma cell line (ISOS-1) in a 5 days-period with IC50 of 0.25 μg/mL. Cell growth of normal murine microvascular endothelial cells (mECs) is less sensitive to Etoposide with IC50 of 10 μg/mL). [2] Etoposide treated for 6 hr inhibits colonies of tetraploid variant of the human leukemic lymphoblast line CCRF-CEM with IC50 of 0.6 μM. [3] Etoposide treated for 2 hr inhibits growth of human pancreatic cancer cell line Y1, Y3, Y5, Y19, YM. YS, and YT with IC50s of 300 μg/mL, 300 μg/mL, 300 μg/mL, 91 μg/mL, 0.68 μg/mL, 300 μg/mL, 300 μg/mL, and 260 μg/mL, respectively. [4] Etoposide exposed for 1 hr inhibits growth of human glioma cell lines CL5, G142, G152, G111, and G5 with IC50 of 8, 9, 9.8, 10, and 15.8 μg/mL respectively for 12 days. Under same condition, the IC90 value is attained in cell lines CL5, G152, G142, and G111 at 26, 27, 32, and 33 μg/mL. Etoposide inhibition of topoisomerase II is homogeneous for each cell. The average inhibition rates are 15%, 21.8%, 31.8%, 41.5%, and 49.5% for 1, 2, 4, 8, and 16 μg Etoposide, respectively. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Kelly NV61PY9pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFHL[pBKSzVyPUCuNVLjiIoEsfMAjVAvODFizszN M{nXdFI2QTZyMkiy
KellyCis83 M2PrOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXWTWM2OD1yLkG25qCKyrIkgJmwMlAzKM7:TR?= NGK4THUzPTl4MEK4Ni=>
SK-N-AS NF;x[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fDNmlEPTB;MD6yOQKBkcLz4pEJNE4xOyEQvF2= M1LBRlI2QTZyMkiy
SK-N-ASCis24 NWj1bYVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWH6U2xrUUN3ME2wMlU46oDLwsJihKkxNjFzIN88US=> NHq5NIUzPTl4MEK4Ni=>
U87 NWDIcY9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmwMVUxKM7:TR?= MXe0PEBp Mn7H[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIfobYNpKGOjbjDi[UBmdmijbnPl[EBjgSC|aXzpZolvcW5? M37DdVI2PzVyMkez
HCT116 MmrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjDNE42NTJwNTFOwG0> NVjxcHJrPDkEoHlCpC=> NE\SfndKSzVyPUGuO|PDqMLzwrCwMlIyyqEQvF2= MlTjNlU4PDZ5NkO=
HT-29 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\IUFAvPS1{LkWg{txO MofGOFjDqGkEoB?= M{P1RWlEPTB;Nz6yxsDDucLiMT6wOOKh|ryP NYXDbWtqOjV5NE[3OlM>
Caco2 MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWmwMlUuOi53IN88US=> M4LkOlQ5yqCqwrC= NVyxRmh7UUN3ME23MlI3yqEEsdMgNU43QMLizszN MlXkNlU4PDZ5NkO=
COLO 205 NHj4bGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;Uc5oxNjVvMj61JO69VQ>? M2fo[lQ5yqCqwrC= MoDTTWM2OD1zLk[xxsDDucLiMD6wNuKh|ryP NELDdZAzPTd2Nke2Ny=>
SW480 NWHydG42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX2NlUxNjVvMj61JO69VQ>? NHvDdYI1QMLiaNMg MlLLTWM2OD12LkmyxsDDucLiMD6zN:Kh|ryP M1;zWFI2PzR4N{[z
HEK293T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\VTZB5OS13IN88US=> NYnMcWhPPDkEoHlCpC=> NF;RNYNKSzVyPUKuOFLDqMLzwrCwMlA2yqEQvF2= MWqyOVc1Pjd4Mx?=
Hep3B  MYTGeY5kfGmxbjDBd5NigQ>? M{mxUVExKM7:TR?= NXrRN4hHPDkEoHlCpC=> NV\KdYN6emWmdXPld{B1cGViZX7oZY5kcW6pIHXm[oVkfCCxZjDCUXAuPg>? MVqyOVY{OzV4NB?=
Hep3B  NXH5TJczTnWwY4Tpc44hSXO|YYm= M1P5WVAvOS1zMDFOwG0> MXGyOEBp NW\SS45{e3WycILld5NmeyC2aHWg[ZhxemW|c3nvckBw\iCqZYDjbYRqdiCvUl7B M37sU|I2PjN|NU[0
HEK293 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnKTWM2OD15LkG0xsDDucLiMD6zOuKh|ryP MofLNlU3ODNzMkK=
DU145 MkD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;GTWM2OD1{LkK4xsDDucLiMD6wOOKh|ryP M3rzNlI2PjB|MUKy
HCT15 M4S0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWz[4Q6UUN3ME2wMlgyyqEEsdMgNE4xOcLizszN NVvOOm1jOjV4MEOxNlI>
T47D MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;5bGlEPTB;Mz6xPOKhyrIEoECuNVHDqM7:TR?= MYKyOVYxOzF{Mh?=
SMMC-7721 MXLGeY5kfGmxbjDBd5NigQ>? MlPjOFAh|ryP M4DkcFQ5KGh? MVXEUXNQ Ml[5bY5lfWOnczFOt2gzSVhiZn;jbUBnd3KvYYTpc44> M3PHPVI2PTR2M{[x
MDA-MB-231 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLTfmw4OsLiaB?= Mlq1TWM2OD1{MT6yxsDDucLiND6yxsDPxE1? MoDWNlU1QDZ{MUm=
MCF-7 NEK4[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG3NuKhcA>? Mnf1TWM2OD1zMD65xsDDucLiMj6xxsDPxE1? MXGyOVQ5PjJzOR?=
Jurkat MmLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[3NuKhcA>? M1joTGlEPTB;MT6yxsDDucLiMT61xsDPxE1? MoK4NlU1QDZ{MUm=
HeLa NFrIb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnv[po4OsLiaB?= MX;JR|UxRTNwOdMgxtHDqDJwM9Mg{txO MlPQNlU1QDZ{MUm=
MCF7  M2HqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYi1MVExOCEQvF2= M{C2Vlch\A>? MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MViyOVQ4OjZzOR?=
K562 NGjRT2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;sO|LDqGh? NUjjT|JUUUN3ME2wMlI6yqEQvF2= MV2yOVI5OjZ3Mx?=
K/VP.5 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnxOHUxPzMEoHi= MV\JR|UxRTRwOdMg{txO MmrzNlUzQDJ4NUO=
SH-EP  M4W5VmZ2dmO2aX;uJGF{e2G7 NHL0WFIzOMLizsznM41t M1Tz[|I1yqCq NHPhPJFqdmO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4Yh\W6mb3flco92eyCGRWDQ Mn7tNlUzPjF7OEG=
SCC25 NUjm[GhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljaNlTDqGh? MV3JR|UxRTR|LkRCpOKyyqBzLkGyxsDPxE1? NYTLT5NUOjV{MkC3Nlk>
CAL27 M{foTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmT4NlTDqGh? NV23XHh7UUN3ME21Nk4yyqEEsdMgNU4xQcLizszN MY[yOVIzODd{OR?=
FaDu M1XpcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TjSlI1yqCq NYnRUWdGUUN3ME2yOU45QcLiwsJCpFEvOTQEoN88US=> NGP4O5QzPTJ{MEeyPS=>
SCC25 NEjSdYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnLMOFjDqGh? NWrYWnRRUUN3ME2yNE45PsLiwsJCpFEvODgEoN88US=> M2PVZVI2OjJyN{K5
CAL27 NEPOTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYW0POKhcA>? NXvkPZo6UUN3ME2xPE4zPMLiwsJCpFEvOTYEoN88US=> NHTSfXEzPTJ{MEeyPS=>
FaDu MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHrSow1QMLiaB?= MVrJR|UxRTZwNERCpOKyyqBzLkGzxsDPxE1? NH3xNm4zPTJ{MEeyPS=>
SCC25 MnThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWq3NuKhcA>? NXHnZ25SUUN3ME24MlQyyqEEsdMgNU4yOcLizszN NX3DTow2OjV{MkC3Nlk>
CAL27 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY[3NuKhcA>? NYTWfYxIUUN3ME20MlI4yqEEsdMgNU4yPMLizszN M4KwUFI2OjJyN{K5
FaDu NUPqdlNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYq3NuKhcA>? M2jGS2lEPTB;NT6wNuKhyrIEoEGuNVXDqM7:TR?= NHHD[IYzPTJ{MEeyPS=>
MCF-7 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInjVFE1QMLiaNMg M3LZZWROW09? NX\vWYY2UUN3ME23MlLDqMLzwrCwMljDqM7:TR?= NEC4bVczPTJzNkO3PC=>
T-47D MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zaVlQ5yqCqwrC= M2PNTmROW09? M4HWW2lEPTB;Nz63xsDDucLiMD63xsDPxE1? NVHHUotqOjV{MU[zO|g>
MDA-MB-231 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPqOFjDqGkEoB?= NU\ibJFsTE2VTx?= M4j6N2lEPTB;MUKuPOKhyrIEoEGuNOKh|ryP MWOyOVIyPjN5OB?=
DU145 MWDBdI9xfG:|aYOgRZN{[Xl? NHPnc3UyOC1zMECg{txO NHL1eHU5KGh? Ml;6SG1UVw>? MVnpcoR2[2W|IHPlcIwh\GWjdHigd4lodmmoaXPhcpRtgSCrbjDhJJZmenlibH;3JINwdmOnboTyZZRqd25? NGLiT2MzPTF2OU[4NS=>
DU145 stem-like Mn7BRZBweHSxc3nzJGF{e2G7 NVrTdJJXOTBvMUCwJO69VQ>? NXrzem1SQCCq NVjBOIVHTE2VTx?= MoHsbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M{jsc|I2OTR7Nkix
DU145 MVrGeY5kfGmxbjDBd5NigQ>? NITEU20yOC1zMECg{txO NF:1W4UzKGh? NVnwbJR7TE2VTx?= M3W2b4lv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MYqyOVE1QTZ6MR?=
DU145 stem-like M3rsUWZ2dmO2aX;uJGF{e2G7 MVmxNE0yODBizszN NHLDV2ozKGh? MX\EUXNQ M3LaWolv[3KnYYPld{B1cGVicFPIT|Eh\XiycnXzd4lwdiCjbnSg[IVkemWjc3XzJJRp\SCyQ1jLNUBmgHC{ZYPzbY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M4\ITlI2OTR7Nkix
UW228-3 NGfBV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXKwMlAyNTNyMDFOwG0> MVm0PEBp M{DlfWROW09? NU[4dlBUUUN3ME2wMlk6yqEQvF2= MonqNlUyOTlzOEW=
NSCs MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnINE4xOS1|MECg{txO MUS0PEBp M1P5[GROW09? NGfheYhKSzVyPUCuN{0{yqEQvF2= M2rROFI2OTF7MUi1
MKL-1  MmH1SpVv[3Srb36gRZN{[Xl? NI[zdYUyOC1zMECwJI5O NWPp[|NtPCCm NH;ORolqdmS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gUWhENUliZYjwdoV{e2mxbh?= MWCyOVEyPjd3NB?=
MCF7 EV NIrUV5lHfW6ldHnvckBCe3OjeR?= NEX4WXQyOC1zMECg{txO NV3rPVg4OuLCiXi= NHnaW4xqdmS3Y3XzJJBzd2S3Y4Tpc44hd2cEoN8zTFJCYA>? M4e4UlI2ODh6MkCz
MCF 7BMI1 MorDSpVv[3Srb36gRZN{[Xl? MkDwNVAuOTByIN88US=> NEDk[HIz6oDLaB?= M4[zeYlv\HWlZYOgdJJw\HWldHnvckBw\sLizsPINmFZ MkniNlUxQDh{MEO=
MCF7 EV MoXzSpVv[3Srb36gRZN{[Xl? MmLUNVAuOTByIN88US=> M3rwOFLjiImq NXTafYViTVSRUDDpcoR2[2W|IFHUUUBi[3SrdnH0bY9v NFXqUm0zPTB6OEKwNy=>
MCF7 BMI1 NYCy[4VmTnWwY4Tpc44hSXO|YYm= MYCxNE0yODBizszN NXXFb5pyOuLCiXi= NFLMfGNGXE:SIHnu[JVk\XNiQWTNJIFkfGm4YYTpc44> MnHwNlUxQDh{MEO=
HepG2 NELGU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnEUXNQyqB? M1z6OGlEPTB;M{CuNVbDqMLzwrCwMlUxyqEQvF2= M2H0N|I2ODd6M{Gx
MOLT-3 M1HEWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjZbnplTE2VT9Mg NULnZ2JKUUN3ME2wMlA2OcLiwsJCpFAvODB{wrFOwG0> NF3OemQzPTB5OEOxNS=>
HT1080 NFKwdmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXyxMVExOCEQvF2= NVj6XJN2PC9{ND:0PEBp MVnEUXNQyqB? M{S5eIlv\HWlZYOgZ4VtdCCmZXH0bEB{cWewaX\pZ4FvfGy7IHnuJIEhfmW{eTDsc5ch[2:wY3XueJJifGmxbh?= NFe4enIzPTB5OEC2OC=>
HT1080 MUTGeY5kfGmxbjDBd5NigQ>? NV3YRolwOC5yMECxMVExOCEQvF2= Mn;INU0zPCCq MlnjSG1UV8Li MoDtbY5lfWOnczDwMZA2Oyi|ZYKxOUkhcW5iYn;0bEB1cW2nLTDhcoQh[2:wY3XueJJifGmxbj3k[ZBmdmSnboSgcYFvdmW{ M1jrWVI2ODd6ME[0
HT1080 M3vyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7uSZpGOC5yMECxMVExOCEQvF2= M4DKfFI1KGh? NGLvZ2tFVVORwrC= NEXXe3Bk[XW|ZYOgZY4hcW6lcnXhd4UhcW5idHjlJI52dWKncjDv[kBk\WyuczDpckBIOi:PLDD3bIlt\SCmZXPy[YF{cW6pIGOgZY5lKEdzIIDoZZNmKGOnbHzz M{P4[VI2ODd6ME[0
HD-MY-Z MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPsN21TOjRxNEivO|IhcA>? NU\2RnlIUUN3MP-8olExOCEQvF2= M4XyN|I2ODR6MkO2
DOHH-2 NF[zeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LhXlI1KGh? NYO5d3V2UUN3MP-8olExOCEQvF2= NXX5Ro0yOjVyNEiyN|Y>
DOHH-2 NWDKbmlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoftOFghcA>? NFOzRZNKSzVyPUG5MlnDqM7:TR?= NVy3NFV7OjVyNEiyN|Y>
DOHH-2 NGnMXIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXDO|IhcA>? NEjFdoJKSzVyPUZCpO69VQ>? NVrsU2pbOjVyNEiyN|Y>
REH MnvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HCdFI1KGh? NF\T[|JKSzVyPUCuNFI4yqEQvF2= NHnrfJczPTB2OEKzOi=>
REH NV7aeG5XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTZOFghcA>? MXvJR|UxRTBwMEG0xsDPxE1? MX2yOVA1QDJ|Nh?=
REH MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe3NkBp NFHKN4NKSzVyPUCuNFE2yqEQvF2= MYCyOVA1QDJ|Nh?=
HH M1rSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHaXYEzPCCq MV7JR|UxRTFyND63xsDPxE1? Mn\GNlUxPDh{M{[=
HH Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofoOFghcA>? NVLUTIpiUUN3ME20PE43yqEQvF2= MUiyOVA1QDJ|Nh?=
HH NEXZNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVq3NkBp M{HrbmlEPTB;MUSuO:Kh|ryP NH\MUYwzPTB2OEKzOi=>
HuT-78 NITlWIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3POdFI1KGh? NHjvXI9KSzVyPUmuN:Kh|ryP M1\TT|I2ODR6MkO2
HuT-78 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYW0PEBp NEL4RZNKSzVyPUSuN:Kh|ryP Mm\WNlUxPDh{M{[=
HuT-78 MkXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLiO|IhcA>? NXLTVW9TUUN3ME20MlLDqM7:TR?= NHjBOHczPTB2OEKzOi=>
OPM-2 MlrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXzNlQhcA>? MUfJR|UxRTJ2LkJCpO69VQ>? M2PJV|I2ODR6MkO2
OPM-2 NWLuVodNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYW0PEBp M3PlcGlEPTB;NNMg{txO MkjhNlUxPDh{M{[=
OPM-2 NXn0SpU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH60PVY4OiCq M1\3[GlEPTB;MT6zxsDPxE1? M4fCWVI2ODR6MkO2
RPMI-8226 M{\nXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PLPFI1KGh? MYTJR|UxRTFyNj62xsDPxE1? NYnTVnpNOjVyNEiyN|Y>
RPMI-8226 NYX4TXhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rUV|Q5KGh? MXTJR|UxRTlzLkJCpO69VQ>? M{jafVI2ODR6MkO2
RPMI-8226 NEf6UYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHiO|IhcA>? MV\JR|UxRTF2LkpCpO69VQ>? MmXSNlUxPDh{M{[=
U-266 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3UXm4zPCCq NV\ZXIY6UUN3ME24Ok4zyqEQvF2= NWXtbll2OjVyNEiyN|Y>
U-266 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXW4TWd7PDhiaB?= NGnLUG1KSzVyPU[4MlTDqM7:TR?= M{O5[VI2ODR6MkO2
U-266 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;We3g5PzJiaB?= MVPJR|UxRTJ5LkVCpO69VQ>? NYj1R4tDOjVyNEiyN|Y>
Kelly NWHIcllpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLZNE0yOCEQvF2= NYnDVGNbPzMEoHi= M{DwSmlEPTB;MT61NVjDqM7:TR?= Mn:0NlUxODh7MEC=
SH-SY5Y  M3XUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33FNlAuOTBizszN MVO3NuKhcA>? MXPJR|UxRTBwN{W0xsDPxE4EoB?= NXPnRYdGOjVyMEi5NFA>
SK-N-AS NYXQfJdMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWmwMVExKM7:TR?= MYW3NuKhcA>? M3nmemlEPTB;MT63NVLDqM7:TdMg NGHQUZkzPTByOEmwNC=>
SK-N-DZ MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf0VVgxNTFyIN88US=> NW[2NnBuPzMEoHi= MmHvTWM2OD13LkS4OeKh|ryP NUfVZ|FqOjVyMEi5NFA>
HepG2 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\lOFQ5yqCq MnzySG1UV8Li MWXJR|UxRTF|Lk[1xsDDucLiMD65NuKh|ryP NHyxdnYzPDl7NkGzOi=>
A549 NXHh[|Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWG0POKhcA>? MWXEUXNQyqB? Mo\ZTWM2OD1{NEGuPeKhyrIEoEOxMlI{yqEQvF2= MofoNlQ6QTZzM{[=
MCF7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[2b4o1QMLiaB?= M2fwbmROW00EoB?= MU\JR|UxRThzLkC5xsDDucLiMUSuNlHDqM7:TR?= NYT1RotTOjR7OU[xN|Y>
HL-60  NED4XJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LTPFczyqCq MmXnTWM2OD1yLkGy5qCG|ryP M4f4U|I1QTl|MEG0
HL-60[R] NYLudo5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTIO|LDqGh? MlHjTWM2OD1|LkGy5qCG|ryP MV6yOFk6OzBzNB?=
MIAPACA NEDjcJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIroR4tIUTVyPUGuN{DDuSByLkCzJO69VQ>? NGDjWVIzPDl3M{iyNS=>
MCF-7 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe0XJdxT0l3ME2wMlI2KMLzIECuNUDPxE1? M2rY[FI1QTV|OEKx
HeLa M4SwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjZT|ZIUTVyPUCuOlQhyrFiMD60JO69VQ>? M4qyc|I1QTV|OEKx
MO59K  MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Lrclch\A>? MmmwTWM2OD1yLkG35qCG|ryP MWSyOFk2OzV4MR?=
MO59J MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jYUlch\A>? NXnmZWNmUUN3ME2wMlHjiIYQvF2= NETj[HIzPDl3M{W2NS=>
ME 180 M33sd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfLcpNNPDkEoHlCpC=> NH\DXWpKSzVyPUiuPeKhyrIEoECuN-KBjc7:TR?= MnTlNlQ6PTNyMke=
MCF-7 NEPZcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDOeWk1QMLiaNMg M4T4XGlEPTB;MkOuPUDDuSByLkRihKXPxE1? MoPJNlQ6PTNyMke=
HeLa M2i1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVuxXXhTPDkEoHlCpC=> NXjKWmd{UUN3ME20MlcyKMLzIEGuOQKBjc7:TR?= MofCNlQ6PTNyMke=
MDA-MB-453 M2Hwcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlz0OFjDqGkEoB?= NXu1OZJmUUN3ME2xNk42KMLzIECuPFXjiIYQvF2= MorCNlQ6PTNyMke=
MDA-MB-231 M{XYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDwW5U1QMLiaNMg MoC4TWM2OD1{ND6yNkDDuSB{Lkm05qCG|ryP M{\KN|I1QTV|MEK3
PC-3 NWHq[JM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37yXFQ5yqCqwrC= NY\hOohrUUN3ME2xOE41KMLzIEOuNlPjiIYQvF2= NEL6bGMzPDl3M{CyOy=>
HT-29 M37LeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4K3TVQ5yqCqwrC= M1;zNmlEPTB;MkGuOFUhyrFiMz64O-KBjc7:TR?= NH76fXAzPDl3M{CyOy=>
BGC-823 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHSOFjDqGkEoB?= NHrXOHRKSzVyPUSzMlc1KMLzIEWuNVPjiIYQvF2= MXiyOFc6Ozh5Nx?=
HeLa NIHBbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECwNWE1QMLiaNMg M3jxUmlEPTB;MkC5MlkxKMLzIEGzMlQzKOLChd88US=> Mnf5NlQ4QTN6N{e=
A549 NHjzb|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe0POKhcMLi NHq3[mdKSzVyPUGzPU42PCEEsTC3MlA26oDHzszN MojwNlQ4QTN6N{e=
HK-2 MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7C[oo5PDkEoHlCpC=> NUDFSGFMUUN3ME25MlE4KMLzIEGuOVjjiIYQvF2= NIDLOo8zPDd7M{i3Oy=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p53 / p-p53 / Acetyl-p53 / TF-IIB; 

PubMed: 23800173     


Western blotting analysis of p53 levels and the indicated p53 post-translational modifications in the nucleus and cytoplasm of U-2 OS cells treated with no drug, 1 μmol/l etoposide (treated for 24 hours) and 100 μmol/l etoposide (treated for 12 hours), re䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ뙠ෆ䐺痖暼瘿뙠ෆᾰƌ 뙠ෆÐ㺣

p53 / p21 / c-Myc / PARP ; 

PubMed: 20212154     


Myc is repressed at the posttranscriptional level following etoposide treatment. HEK293 cells were treated with etoposide at the indicated concentrations for 24 h. Parallel samples were taken for western and northern analysis as indicated. 

23800173 20212154
Immunofluorescence
COX IV; 

PubMed: 29221178     


Panel 1 (untreated) depicts the mitochondrial distribution by visualizing the expression of Cox IV in U87(WT) cells. Panel 2 (etoposide treated) represents the distribution of mitochondria in U87(RETO) cells after 10 days of drug exposure as visualized by䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ

γH2AX / pATM ; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization (yellow signal in the overlay (OL)) of gH2AX (red) and pATM (green). Scale bar = 20 μm.

MDC1; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with MDC1.

pDNA-PKcs; 

PubMed: 19858003     


HeLa cells were treated with vehicle (Ctl), 6 Gy IR (IR) or 25 μM etoposide (ETO). Co-localization of gH2AX with pDNA-PK.

p53; 

PubMed: 27515249     


p53 localization in untreated and 12-h etoposide treated CD41+ MK cells. Cells were stained with anti-p53 antibody. TOTO-3 was used to stain the nucleus. Scale bar=20 μm.

YAP; 

PubMed: 27515249     


(D) YAP localization in untreated CD41+MK cells and CD41+ MK cells treated by 10 μM etoposide for five hours on day 10 of culture. Cells were stained with anti-YAP antibody. DAPI was used to stain the nucleus. Cells (150) were counted and categorized acco䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ삨Ղ䐺痖暼瘿삨Ղᾰƌ 삨ՂÐ㺣痖삨Ղ€𢡄사Ղ€䀷痗사Ղ౴사Ղ㵶痗사Ղ뺖᎒泌Itemセ᎒Count﫨呂샜Ղ

29221178 19858003 27515249
Growth inhibition assay
Cell viability ; 

PubMed: 22615609     


Effect of etoposide on HEK293 cell viability. Cells were seeded at 104 in 96-well plates and treated with etoposide (50,100,150 and 200µM) for 24 hrs and compared to nontreated cells (control). At the end of treatment period, cell viability was measured u䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒

22615609
In vivo Etoposide administrated as a single agent is found to been ineffective in many xenografts growth, such as Heterotransplanted Hepatoblastoma NMHB1, and NMHB 2, [6] human neuroblastoma xenograft, [7] and human gastrointestinal cancer xenograft, [8] while the dose of 10 mg/kg i.p. Etoposide inhibits murine angiosarcoma cell ISOS-1 tumors in 36% of controls. [2] Etoposide induces tumor immunity in Lewis lung cancer. A single administration of 50 mg/kg Etoposide i.p., induces a 60% survival of C57B1/6 mice injected with Lewis lung cancer cell (3LL) over 60 days. About 40% of these surviving mice reject a subsequent challenge with 3LL, while none of control mice survive beyond 30 days. 3LL cells which have survived an 90% lethal concentration of Etoposide in vitro kill 75% of recipient mice, but 60% surviving mice reject challenge with 3LL. Splenocytes harvested from tumor rejecting mice protect naive mice injected with 3LL. [9]

Protocol

Kinase Assay:[5]
- Collapse

Topoisomerase II activity assay:

Nuclear extracts are prepared, and nuclei are isolated. The activity of topoisomerase II is calculated from the percentage of decatenation obtained. Tritiated kinoplast DNA (KDNA 0.22 μg) is used as a substrate. Etoposide and topoisomerase II are incubated for 30 min at 37 ℃ and are stopped with 1% sodium dodecyl sulfate (SDS) and proteinase K (100 μg/mL). The percentages of decatenation and inhibition of topoisomerase II by Etoposide are obtained.
Cell Research:[5]
- Collapse
  • Cell lines: Human glioma cell lines CL5
  • Concentrations: 80 μg/mL
  • Incubation Time: 1 hour
  • Method: After the Etoposide treatment, cells are removed from the dish with phosphate-buffered saline (PBS) containing 0.03% trypsin and 0.27 mM ethylenediaminetetraacetic acid (EDTA) and are diluted into culture dishes in appropriate numbers to yield between 20 and 200 colonies. After 12 days, cultures are fixed with methanol-acetic acid, stained with crystal violet, and scored for colonies containing more than 50 cells. The standard errors are typically less than 15% of the mean value unless otherwise stated.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Murine angiosarcoma xenografts ISOS-1
  • Formulation: Saline
  • Dosages: 10 mg/kg
  • Administration: i.p. every day for 5 days from day 7
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (169.9 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+40% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 588.56
Formula

C29H32O13

CAS No. 33419-42-0
Storage powder
in solvent
Synonyms VP-16, VP-16213
Smiles COC1=CC(=CC(=C1O)OC)C2C3C(COC3=O)C(OC4OC5COC(C)OC5C(O)C4O)C6=C2C=C7OCOC7=C6

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03264131 Recruiting Drug: Brentuximab Vedotin|Drug: CHEP Lymphoma|Adult T-Cell Leukemia/Lymphoma|Lymphatic Diseases UNC Lineberger Comprehensive Cancer Center|Seattle Genetics Inc. October 15 2018 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Regarding the Etoposide S1225, do you have any data of the inhibition sepcificity of this product? It will inhibit other enzymes other than TOP2A?

  • Answer:

    According to the available published data, the inhibition of Etoposide is specific to TOP2A. But there're also two papers showing that Etoposide could inhibit the p34cdc2 Kinase Activity: 1. http://cancerres.aacrjournals.org/content/52/7/1817.short ; 2. http://cancerres.aacrjournals.org/content/50/12/3761.short.

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Etoposide | Etoposide supplier | purchase Etoposide | Etoposide cost | Etoposide manufacturer | order Etoposide | Etoposide distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID